. A month later when maintenance haemodialysis was started, one of these areas on the posterior aspect of the right lower leg rapidly increased in size and developed into a necrotising ulcer which became so painful that the patient was incapacitated and had to be treated with morphine. Moreover, generalised itching appeared. Using mammographic techniques we saw an impressive network of calcified small soft-tissue vessels in both legs with preponderance on the right side (figure). Biopsy showed necrosis, abundant calcium deposits in the subcutaneous fat, and considerable medial calcification and intimal proliferation in small arteries. Serum calcium was 2-6 mmol/l (10-2 mg/100 ml), phosphorus between 1 0 and 1-6 mmol/l (3-1-5-0 mg/l00 ml), alkaline phosphatase 50 IU (normal range <42 IU). Serum parathyroid hormone was considerably raised at 1650 ng/ml (normal .40 ng/ml). On 19 February 1976 three parathyroid glands were removed that showed nodular, adenomatous hyperplasia. Postoperatively serum calcium dropped to 2-2 ,mol/l (90 mg/100 ml), alkaline phosphatase to 28 IU, and serum parathyroid hormone to 210 and 182 ng/ml on March 3 and May 18 1976, respectively. Two days after operation the itching had disappeared and the patient was without pain. The ulcers had healed completely within three weeks.
Mammographic picture of right lower leg in case 2 showing extensive network of calcified small soft tissue vessels.
Discussion
Two different types of skin ulceration occur in azotaemic hyperparathyroidism. The first consists of cutaneous or subcutaneous calcified plaques, and the second of ischaemic necrosis of the skin.5
The rarity of the syndrome complicated diagnosis in our two patients. GChristensson, T, thesis, Stockholm, 1975. 2 Hedstrand, H, Uppsala3Journal of Medical Science, 1975, suppl 19. 3Ljunghall, S, and Hedstrand, H, British Medical3Journal, 1975, 4, 580. 4 Hilton, S M, Circulation Research, 1971, 28, Combination chemotherapy for thrombocytopenia with bone marrow metastases from breast cancer Many chemotherapeutic regimens induce remission in metastatic breast cancer. All are myelotoxic and are not usually used in patients with inadequate bone marrow function. We describe successful cytotoxic treatment with vincristine, doxorubicin, and prednisolone (VDP) offour consecutive cases ofthrombocytopenia with bone marrow metastases from breast cancer.
Patients and methods
Treatment was repeated every 28 days (see figure) . Intravenous vincristine 1-4 mg/M2 (maximum dose 2 mg) and doxorubicin 40 mg/M2 (maximum dose 100 mg) were given on days 1 and 8, although some patients received a single injection initially. Oral prednisolone 20 mg daily was given on days 1-14. Case 1-A woman aged 36 presented with metastatic breast cancer, malignant infiltration of the bone marrow, and thrombocytopenia. Oophorectomy was performed but 10 weeks later thrombocytopenia (46 x 109/1 (46 000/ mm3)) and bone marrow infiltration persisted. The platelet count steadily improved with VDP (single injection for the first course), and after eight months remained normal with complete tumour remission.
Case 2-Four years after mastectomy for breast cancer a 63-year-old woman developed thrombocytopenia. The bone marrow was infiltrated by malignant cells. She responded transiently to nandrolone and prednisolone but six weeks after stopping androgen treatment the platelet count was 42 x 109/1 (42 000/mm3). It 
Comment
Thrombocytopenia and bone marrow metastases from breast cancer have been successfully treated with a combination of high-dose prednisone, ovariectomy, adrenalectomy, and 5-fluorouracil.1 All our patients treated with VDP developed neutropenia, with septicaemia in two cases. All required blood transfusion, but not platelets or granulocytes. There were no other complications.
Transient thrombocytosis after treatment with Vinca alkaloids has been reported in animals and man.2 This is unlikely to have caused the prolonged increase in platelets in our patients. Tumour cells are probably more sensitive to chemotherapy than platelet precursors, which may be suppressed by the tumour in the marrow. Thus patients with bone marrow metastases should be given the most effective antitumour treatment available. We gave combined chemotherapy with VDP because we have found it effective against metastatic breast cancer.; The results suggest that it may be effective in bone marrow depression with malignant bone marrow infiltration. This does not apply to non-metastatic marrow aplasia.
